BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30477238)

  • 1. Kinase Inhibitory Activities and Molecular Docking of a Novel Series of Anticancer Pyrazole Derivatives.
    Nossier ES; Abd El-Karim SS; Khalifa NM; El-Sayed AS; Hassan ESI; El-Hallouty SM
    Molecules; 2018 Nov; 23(12):. PubMed ID: 30477238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.
    Wang SF; Zhu YL; Zhu PT; Makawana JA; Zhang YL; Zhao MY; Lv PC; Zhu HL
    Bioorg Med Chem; 2014 Nov; 22(21):6201-8. PubMed ID: 25267006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, in vitro Antiproliferative and Antiinflammatory Activities, and Kinase Inhibitory effects of New 1,3,4-triarylpyrazole Derivatives.
    El-Gamal MI; Abdel-Maksoud MS; Gamal El-Din MM; Shin JS; Lee KT; Yoo KH; Oh CH
    Anticancer Agents Med Chem; 2017; 17(1):75-84. PubMed ID: 27334850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, biological evaluation of novel 4,5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors.
    Liu JJ; Zhang H; Sun J; Wang ZC; Yang YS; Li DD; Zhang F; Gong HB; Zhu HL
    Bioorg Med Chem; 2012 Oct; 20(20):6089-96. PubMed ID: 22985957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, biological evaluation and 3D-QSAR study of novel 4,5-dihydro-1H-pyrazole thiazole derivatives as BRAF(V⁶⁰⁰E) inhibitors.
    Zhao MY; Yin Y; Yu XW; Sangani CB; Wang SF; Lu AM; Yang LF; Lv PC; Jiang MG; Zhu HL
    Bioorg Med Chem; 2015 Jan; 23(1):46-54. PubMed ID: 25496804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-Substituted-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives: design, synthesis, antitumor and EGFR tyrosine kinase inhibitory activity.
    Abbas SE; Aly EI; Awadallah FM; Mahmoud WR
    Chem Biol Drug Des; 2015 May; 85(5):608-22. PubMed ID: 25318985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
    Davis GD; Vasanthi AH
    Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors.
    Akhtar MJ; Khan AA; Ali Z; Dewangan RP; Rafi M; Hassan MQ; Akhtar MS; Siddiqui AA; Partap S; Pasha S; Yar MS
    Bioorg Chem; 2018 Aug; 78():158-169. PubMed ID: 29571113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors.
    Ravula P; Vamaraju HB; Paturi M; Sharath Chandra JNGN
    Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29205467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and in vitro antiproliferative and kinase inhibitory effects of pyrimidinylpyrazole derivatives terminating with arylsulfonamido or cyclic sulfamide substituents.
    Gamal El-Din MM; El-Gamal MI; Abdel-Maksoud MS; Yoo KH; Baek D; Choi J; Lee H; Oh CH
    J Enzyme Inhib Med Chem; 2016; 31(sup2):111-122. PubMed ID: 27255180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, broad-spectrum antiproliferative activity, and kinase inhibitory effect of triarylpyrazole derivatives possessing arylamides or arylureas moieties.
    Gamal El-Din MM; El-Gamal MI; Abdel-Maksoud MS; Yoo KH; Oh CH
    Eur J Med Chem; 2016 Aug; 119():122-31. PubMed ID: 27155467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of N-(benzyloxy)-1,3-diphenyl-1H-pyrazole-4-carboxamide derivatives as potential antiproliferative agents by inhibiting MEK.
    Lv XH; Ren ZL; Zhou BG; Li QS; Chu MJ; Liu DH; Mo K; Zhang LS; Yao XK; Cao HQ
    Bioorg Med Chem; 2016 Oct; 24(19):4652-4659. PubMed ID: 27515719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel 3,5-diarylpyrazoline derivatives containing salicylamide moiety as potential anti-melanoma agents.
    Li QS; Lv XH; Zhang YB; Dong JJ; Zhou WP; Yang Y; Zhu HL
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6596-601. PubMed ID: 23025996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.
    El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA
    Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of pyrazolyl-nitroimidazole derivatives as potential EGFR/HER-2 kinase inhibitors.
    Tao XX; Duan YT; Chen LW; Tang DJ; Yang MR; Wang PF; Xu C; Zhu HL
    Bioorg Med Chem Lett; 2016 Jan; 26(2):677-683. PubMed ID: 26652482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: Synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies.
    Choi WK; El-Gamal MI; Choi HS; Baek D; Oh CH
    Eur J Med Chem; 2011 Dec; 46(12):5754-62. PubMed ID: 22014559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, in vitro anticancer evaluation, kinase inhibitory effects, and pharmacokinetic profile of new 1,3,4-triarylpyrazole derivatives possessing terminal sulfonamide moiety.
    Abdel-Maksoud MS; El-Gamal MI; Gamal El-Din MM; Oh CH
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):97-109. PubMed ID: 30362383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, biological evaluation and molecular docking studies of pyrazole derivatives coupling with a thiourea moiety as novel CDKs inhibitors.
    Sun J; Lv XH; Qiu HY; Wang YT; Du QR; Li DD; Yang YH; Zhu HL
    Eur J Med Chem; 2013 Oct; 68():1-9. PubMed ID: 23933045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives containing benzodioxole as potential anticancer agents.
    Wang HH; Qiu KM; Cui HE; Yang YS; Yin-Luo ; Xing M; Qiu XY; Bai LF; Zhu HL
    Bioorg Med Chem; 2013 Jan; 21(2):448-55. PubMed ID: 23245802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.